Varsinais-Suomen hyvinvointialue
- Address
- Kiinamyllynkatu 4-8, 20520 Turku, Finland
Varsinais-Suomen Hyvinvointialue - Comprehensive Clinical Research Center
Varsinais-Suomen hyvinvointialue is a leading clinical research institution conducting diverse therapeutic investigations across multiple medical specialties. The center demonstrates particular expertise in oncology research, with extensive trials in both adult and pediatric cancers, as well as advanced neurological studies and infectious disease prevention.
- Comprehensive oncology research including prostate cancer, rectal cancer, leukemias (ALL, AML), lymphomas, medulloblastoma, ependymoma, rhabdomyosarcoma, and Ewing sarcoma with innovative targeted therapies
- Neurological disorder studies focusing on multiple sclerosis with advanced imaging techniques including PET-based microglial activation assessment and novel radiotracer development
- Pediatric research encompassing neonatal brain imaging, childhood cancers, acute wheezing prevention, and maternal-fetal immunology studies
- Inflammatory bowel disease trials exploring fecal microbiota transplantation combined with biologics for ulcerative colitis and Crohn's disease
The center employs cutting-edge diagnostic technologies including USPIO-MRI for lymph node assessment, PSMA-PET imaging for prostate cancer staging, and advanced contrast-enhanced ultrasound techniques for neonatal populations. Their research portfolio includes international multicenter collaborations with organizations such as SIOP, NOPHO, and the International BFM Study Group, demonstrating their commitment to advancing global clinical research standards. The institution's vaccine studies, including pertussis immunity research in both healthcare workers and maternal-infant populations, further highlight their dedication to preventive medicine and public health initiatives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 104 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 99 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Varsinais-Suomen hyvinvointialue6active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Varsinais-Suomen hyvinvointialue10trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Varsinais-Suomen hyvinvointialue
lock Showing 1 of 37 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) | Karolinska University Hospital | Phase IV | Recruiting | Jul 2020 | — |
IMP list
lock Showing 1 of 104 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 6 | Unknown | 2015-05-05 | 2024-09-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.